You are here:
Obesity disrupts mesenteric lymphatic function, promoting visceral fat inflammation and insulin resistance, with potential for targeted therapies to treat metabolic diseases
A prodrug strategy that targets intestinal lymph vessels enhances oral bioavailability by bypassing first-pass metabolism, increasing drug plasma exposure
Tumour-targeting nanobodies enhance dendrimer drug delivery, improving uptake and therapy while preserving circulatory advantages
The lymphatic system's role in metabolism, immunity, and disease has led to advancements in lymph-targeted therapies using nanotechnology-based delivery systems.
Endosomal signaling of the NK1R receptor plays a key role in pain transmission, and endosomal-targeted NK1R antagonists provide more effective and sustained pain relief than conventional treatments.
